31P-MRS Myocardial Energetic Phenotyping and Prognosis Across the Cardiac Disease Spectrum

Brief summary (registry, in English)

The study is designed to establish a comprehensive myocardial energetic phenotype across a broad spectrum of cardiovascular diseases using phosphorus-31 magnetic resonance spectroscopy (31P-MRS). And the study plans to enroll 1,000 participants, comprising healthy volunteers and patients with diverse cardiac conditions. Target cohorts primarily encompass heart failure syndromes and various cardiomyopathies, with a particular focus on non-ischemic and hypertrophic phenotypes, as well as ischemic and other structural etiologies. By integrating 31-MRS with multiparametric standard CMR, this study aims to map disease-specific metabolic signatures. The primary outcome measure is the myocardial PCr/ATP ratio, serving as a direct in vivo marker of energetic impairment. Furthermore, the study aims to explore the coupling between metabolic phenotypes and structural remodeling (tissue characterization), mechanical dysfunction, and systemic clinical biomarkers. Crucially, the study will evaluate the prognostic value of these energetic phenotypes in predicting clinical outcomes, ultimately providing novel insights into the pathophysiology and risk stratification of cardiomyopathies and heart failure.

What you commit to

• Study type: Observational
• Planned participants: 1000
• From 1 Aug 2025 to the primary completion date, 1 Sept 2030
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.